Core Viewpoint - Recently, Tianjin Lifesun Pharmaceutical Co., Ltd. received a notification from the National Medical Products Administration regarding the approval of the supplementary application for Aminophylline Tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved specification for the drug is 0.1g, calculated based on C₂H₈N₂(C₇H₈N₄O₂)₂·2H₂O [1]

Core Viewpoint - Lisheng Pharmaceutical has received approval from the National Medical Products Administration for its 0.1g specification of Aminophylline tablets, which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Product Approval - The approval notification pertains to Aminophylline tablets, which are indicated for the relief of symptoms in bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema [1] - The drug is also applicable for asthma caused by cardiogenic pulmonary edema [1]

Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]

证券代码：002393 证券简称：力生制药 公告编号：2026-007 天津力生制药股份有限公司 关于药品氨茶碱片通过仿制药一致性评价的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概况 近日，天津力生制药股份有限公司（以下简称"本公司"）收到国家药品监督管理局 颁发的关于氨茶碱片（以下简称"该药品"）0.1g（按 C₂H₈N₂(C₇H₈N₄O₂)₂·2H₂O 计）规 格的《药品补充申请批准通知书》（批件号：2026B00421），该药品通过仿制药质量 和疗效一致性评价。 二、该药品的基本情况 规格：0.1g（按C₂H₈N₂(C₇H₈N₄O₂)₂·2H₂O计） 注册分类：化学药品 药品生产企业：天津力生制药股份有限公司 原药品批准文号：国药准字H12020118 申请内容：仿制药质量和疗效一致性评价 受理号：CYHB2550123 审批结论：通过仿制药质量和疗效一致性评价。 三、该药品的相关信息 氨茶碱片适应症： 药品名称：氨茶碱片 剂型：片剂 公司该药品通过仿制药质量和疗效一致性评价，有利于提升该药品市场竞争力。由 于医药产品的行业特点，各类产品 ...

力生制药公告称，公司收到国家药监局颁发的氨茶碱片0.1g规格的《药品补充申请批准通知书》，该药 品通过仿制药质量和疗效一致性评价。此药适用于缓解支气管哮喘等喘息症状，也可用于心源性肺水肿 引起的哮喘。公司表示，该药品通过评价有利于提升市场竞争力，但医药产品销售受市场环境等因素影 响，具有不确定性，提醒投资者注意风险。 ...

Core Viewpoint - The company emphasizes its commitment to fulfilling social responsibilities sustainably while providing quality pharmaceuticals and health services to more patients in alignment with national policies and local needs [1]. Group 1 - The company acknowledges its role as a listed entity in meeting social responsibilities [1]. - Future efforts will focus on integrating national policy directions with local actual needs [1]. - The aim is to ensure that quality medicines and professional health services benefit a larger patient base [1].

Market Overview - The A-share market exhibited a fluctuating and differentiated pattern last week, with major indices showing mixed performance and active rotation among hot sectors [1][7] - Institutions generally hold an optimistic outlook, believing the market is likely to trend upward [1][7] - As of January 25, over 950 companies have disclosed their 2025 earnings forecasts, with around 40% of these companies showing positive performance [1][7] Semiconductor Industry - The semiconductor industry, particularly companies related to artificial intelligence, data center construction, and domestic substitution, is expected to see strong earnings growth in 2025 [1][8] - Notable companies include: - Zhongwei Semiconductor expects revenue of approximately 1.122 billion yuan, a year-on-year increase of about 23%, and a net profit of 284 million yuan, up approximately 107% [8] - Juchip Technology anticipates revenue of 922 million yuan, a 41.44% increase, and a net profit of 204 million yuan, up 91.40% [2] - Baiwei Storage forecasts revenue between 10 billion to 12 billion yuan, a growth of 49.36% to 79.23%, and a net profit of 850 million to 1 billion yuan, a staggering increase of 427.19% to 520.22% [3][9] Pharmaceutical Industry - The pharmaceutical sector is experiencing a "polarized" performance, with over 60 companies disclosing earnings forecasts, about half of which are positive [1][9] - Key performers include: - Zhaoyan New Drug expects a net profit of approximately 233 million to 349 million yuan, a year-on-year increase of 214% to 371% [10] - Shanghai Yizhong anticipates a net profit of 6 million to 7 million yuan, a growth of 760.18% to 903.54% [10] - However, companies like Zhifei Biological are projected to incur significant losses, with an expected net loss of 10.7 billion to 13.7 billion yuan [10][5] Banking Sector - As of January 25, eight listed banks have released earnings reports, with all showing year-on-year growth in net profit [5][11] - Key statistics include: - China Merchants Bank's total assets surpassing 13 trillion yuan, and Industrial Bank exceeding 11 trillion yuan [11] - The highest net profit growth among these banks is from Hangzhou Bank at 12.05%, followed by Shanghai Pudong Development Bank at 10.52% [11] - The growth drivers for banks include improved cost of liabilities and rapid growth in intermediary business income, with Ningbo Bank's net income from fees and commissions increasing by 30.72% [12]

Group 1 - Tianjin Lisheng Pharmaceutical Co., Ltd. has invested 1 million RMB to establish Tianjin Sanyu Clinic Co., Ltd., holding 100% of the shares [1] - Tianjin Sanyu Clinic was established on January 26, 2026, with a registered capital of 1 million RMB and is located in Tianjin [1] - The clinic will provide various services including traditional Chinese medicine, health consultation, and sales of medical devices and health products [1] Group 2 - The clinic's legal representative is Ma Gang, and it will operate under the regulations of the relevant health authorities [1] - The business scope includes both licensed and unlicensed activities, with specific projects requiring approval from relevant departments [1] - The clinic aims to engage in a wide range of health-related services, including patient care and rehabilitation support [1]

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 1.本次回购注销的限制性股票授予日为2022年12月27日，本次回购注销限制性股票数 量共计30,016股，占回购前公司总股本257,616,859股的0.0117%，回购价格为8.76元/股。 2.截至2026年1月27日，上述限制性股票已在中国证券登记结算有限责任公司深圳分公 司办理完回购注销相关手续。 证券代码：002393 证券简称：力生制药 公告编号：2026-006 天津力生制药股份有限公司 关于部分限制性股票回购注销完成暨股份变动的公告 4.2022年11月15日，公司于巨潮资讯网（www.cninfo.com.cn）上披露了《监事会关于 公司2022年限制性股票激励计划授予激励对象名单的公示情况说明及核查意见》（公告编 号：2022-074）。 5.2022年12月5日，公司召开2022年第五次临时股东大会，审议并通过了《关于公司 2022年限制性股票激励计划（草案）及其摘要的提案》《关于公司2022年限制性股票激励 1 计划实施考核管理办法的提案》以及《关于提请公司股东大会授权董事会 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 二、与会计师事务所沟通情况 证券代码：002393 证券简称：力生制药 公告编号：2026-005 天津力生制药股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日-2025年12月31日 2、预计的业绩： √同向上升 3、业绩预告为区间 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所审计。公司已就业绩预告有 关事项与年报审计会计师事务所进行了预沟通，公司与会计师事务所在本报告期的业绩预告方面不存在 分歧。 三、业绩变动原因说明 报告期内，公司持续加大市场拓展力度，产品销售有所提升；加之天士力生物医药产业集团有限公司分 红因素影响，归属于上市公司股东的净利润同比增幅较大。 四、其他相关说明 本次业绩预告是公司财务部门初步核算的结果，具体财务数据以公司披露的2025年度报告为准。敬请广 大投资者审慎决策，注意投资风险。 特此公告。 天津力生制药股份有限公司 董事会 2026年01月24日 ...